10-Q: Quarterly report [Sections 13 or 15(d)]
Published on November 16, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
For the quarterly period ended
For the transition period from ________ to ________
Commission File Number:
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
(Address of principal executive offices, including zip code)
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months.
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
| Large accelerated filer | ☐ | Accelerated filer | ☐ | ☒ | Smaller reporting company | Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No
As of November 16, 2026, there were
TABLE OF CONTENTS
| PART I — FINANCIAL INFORMATION | 1 | |
| Item 1. | Financial Statements (Unaudited) | 1 |
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 2 |
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 5 |
| Item 4. | Controls and Procedures | 5 |
| PART II — OTHER INFORMATION | 6 | |
| Item 1. | Legal Proceedings | 6 |
| Item 1A. | Risk Factors | 6 |
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 6 |
| Item 3. | Defaults Upon Senior Securities | 6 |
| Item 4. | Mine Safety Disclosures | 6 |
| Item 5. | Other Information | 6 |
| Item 6. | Exhibits | 7 |
| SIGNATURES | 8 | |
| i |
PART I — FINANCIAL INFORMATION
Item 1. Financial Statements
INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
| 1 |
Apimeds Pharmaceuticals US, Inc.
Unaudited Condensed Consolidated Balance Sheets
| September 30, 2026 |
December 31, 2025 |
|||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Restricted cash | ||||||||
| Accounts receivable | ||||||||
| Accounts receivable — related party | ||||||||
| Other current assets | ||||||||
| Current assets of discontinued operations | ||||||||
| Total current assets | ||||||||
| Digital assets, at fair value | ||||||||
| Investment in equity securities, at fair value | ||||||||
| Noncurrent assets of discontinued operations | ||||||||
| Total assets | $ | $ | ||||||
| Liabilities and shareholders’ equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable and accrued expenses | $ | $ | ||||||
| Contract liability — related party | ||||||||
| Accrued offering costs | ||||||||
| Advance payable to related party | ||||||||
| Derivative liability | ||||||||
| Convertible notes, net | ||||||||
| Current liabilities of discontinued operations | ||||||||
| Total current liabilities | ||||||||
| Noncurrent liabilities of discontinued operations | ||||||||
| Total liabilities | ||||||||
| Commitments and contingencies (Note 13) | ||||||||
| Shareholders’ equity: | ||||||||
| Series A convertible preferred stock, par value $ | ||||||||
| Common stock, par value $ | ||||||||
| Common shares to be issued | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Total shareholders’ equity | ||||||||
| Total liabilities and shareholders’ equity | $ | $ | ||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
| F-1 |
Apimeds Pharmaceuticals US, Inc.
Unaudited Condensed Consolidated Statements of Operations
| Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenue: | ||||||||||||||||
| Software development and deployment services | $ | $ | $ | $ | ||||||||||||
| Digital asset yield income | ||||||||||||||||
| Total revenue | ||||||||||||||||
| Operating expenses: | ||||||||||||||||
| Cost of revenue | ||||||||||||||||
| General and administrative expenses | ||||||||||||||||
| Income (loss) from operations | ( | ) | ||||||||||||||
| Other income (expense): | ||||||||||||||||
| Unrealized gain (loss) from changes in fair value of digital assets | ( | ) | ||||||||||||||
| Realized gain on sale of digital assets | ||||||||||||||||
| Trading gains, net | ( | ) | ||||||||||||||
| Foreign currency gains (losses), net | ( | ) | ( | ) | ||||||||||||
| Change in fair value of equity securities | ( | ) | ( | ) | ||||||||||||
| Change in fair value of warrant liability | ||||||||||||||||
| Change in fair value of derivative liability | ||||||||||||||||
| Interest income | ||||||||||||||||
| Interest expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Total other income (expense), net | ( | ) | ||||||||||||||
| Income (loss) from continuing operations | ( | ) | ||||||||||||||
| Income (loss) from discontinued operations, net of tax | ( | ) | ( | ) | ( | ) | ||||||||||
| Net income (loss) | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||
| Net income (loss) per common share — basic: | ||||||||||||||||
| Continuing operations | $ | $ | $ | ( | ) | $ | ||||||||||
| Discontinued operations | ( | ) | ( | ) | ( | ) | ||||||||||
| Net income (loss) per common share — basic | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||
| Net income (loss) per common share — diluted: | ||||||||||||||||
| Continuing operations | $ | $ | $ | ( | ) | $ | ||||||||||
| Discontinued operations | ( | ) | ( | ) | ( | ) | ||||||||||
| Net income (loss) per common share — diluted | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||
| Weighted-average common shares outstanding — basic | ||||||||||||||||
| Weighted-average common shares outstanding — diluted | ||||||||||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
| F-2 |
Apimeds Pharmaceuticals US, Inc.
Unaudited Condensed Consolidated Statements of Changes in Shareholders’ Equity (Deficit)
| Preferred Stock | Common Stock | Common Stock Issuable | Additional Paid-in | Accumulated | ||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Deficit | Total | ||||||||||||||||||||||||||||
| Balance at December 31, 2025 | $ | $ | $ | $ | $ | ( | ) | $ | ||||||||||||||||||||||||||||
| Net loss | — | — | — | ( | ) | ( | ) | |||||||||||||||||||||||||||||
| Stock-based compensation | — | — | — | |||||||||||||||||||||||||||||||||
| Shares committed for issuance under advisory agreement | ||||||||||||||||||||||||||||||||||||
| Balance at March 31, 2026 | ( | ) | ||||||||||||||||||||||||||||||||||
| Issuance of common stock under advisory agreement | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
| Stock-based compensation | — | — | — | |||||||||||||||||||||||||||||||||
| Subscription receivable collected on subsidiary shares | — | — | — | |||||||||||||||||||||||||||||||||
| Net loss | — | — | — | — | ( | ) | ( | ) | ||||||||||||||||||||||||||||
| Balance at June 30, 2026 | ( | ) | ||||||||||||||||||||||||||||||||||
| Stock-based compensation | — | — | — | |||||||||||||||||||||||||||||||||
| Reversal of stock-based compensation on forfeited options | — | — | — | ( | ) | ( | ) | |||||||||||||||||||||||||||||
| Common stock issued for fractional-share round-ups in reverse stock split | ( | ) | ||||||||||||||||||||||||||||||||||
| Conversion of convertible notes into common stock | ||||||||||||||||||||||||||||||||||||
| Net income | — | — | — | |||||||||||||||||||||||||||||||||
| Balance at September 30, 2026 | $ | $ | $ | $ | $ | ( | ) | $ | ||||||||||||||||||||||||||||
| Balance at December 31, 2024 | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | ||||||||||||||||||||||||||
| Net loss | — | — | — | — | ( | ) | ( | ) | ||||||||||||||||||||||||||||
| Balance at March 31, 2025 | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||
| Stock-based compensation | — | — | — | |||||||||||||||||||||||||||||||||
| Common stock grants | ||||||||||||||||||||||||||||||||||||
| Conversion of convertible debt | ||||||||||||||||||||||||||||||||||||
| IPO representative warrants | — | — | — | |||||||||||||||||||||||||||||||||
| IPO common stock issuance, net | ||||||||||||||||||||||||||||||||||||
| Net loss | — | — | — | ( | ) | ( | ) | |||||||||||||||||||||||||||||
| Balance at June 30, 2025 | ( | ) | ||||||||||||||||||||||||||||||||||
| Stock-based compensation | — | — | — | |||||||||||||||||||||||||||||||||
| Issuance of advisor warrants in connection with IPO | — | — | — | |||||||||||||||||||||||||||||||||
| Net loss | — | — | — | ( | ) | ( | ) | |||||||||||||||||||||||||||||
| Balance at September 30, 2025 | $ | $ | $ | $ | $ | ( | ) | $ | ||||||||||||||||||||||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
| F-3 |
Apimeds Pharmaceuticals US, Inc.
Unaudited Condensed Consolidated Statements of Cash Flows
| For the Nine Months Ended September 30, |
||||||||
| 2026 | 2025 | |||||||
| Cash flows from operating activities: | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Stock-based compensation | ||||||||
| Stock-based compensation — common stock grants | ||||||||
| Advisory shares committed for issuance | ||||||||
| Depreciation and amortization | ||||||||
| Change in fair value of derivative liability | ( | ) | ( | ) | ||||
| Non-cash interest | ||||||||
| Accretion of debt discounts | ||||||||
| Unrealized (gain) loss from changes in fair value of digital assets | ||||||||
| Realized gain and trading gains on digital assets | ( | ) | ||||||
| Digital assets received as yield income | ( | ) | ||||||
| Proceeds from sales of digital assets, net of purchases | ||||||||
| Gain on deconsolidation of subsidiary | ( | ) | ||||||
| Change in fair value of equity securities | ||||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | ( | ) | ||||||
| Prepaid expenses and other current assets | ( | ) | ||||||
| Accounts payable and accrued expenses | ( | ) | ||||||
| Operating lease liability | ( | ) | ||||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| Cash flows from investing activities: | ||||||||
| Redemption of short-term investments | ||||||||
| Purchases of property and equipment | ( | ) | ( | ) | ||||
| Cash of subsidiary derecognized upon deconsolidation | ( | ) | ||||||
| Net cash provided by (used in) investing activities | ( | ) | ||||||
| Cash flows from financing activities: | ||||||||
| Proceeds from notes payable, net of original issue discount | ||||||||
| Payment of debt issuance costs | ( | ) | ||||||
| Repayment of notes payable | ( | ) | ||||||
| Cash advances from (repayments to) related parties | ( | ) | ||||||
| Proceeds from subscription receivable on subsidiary shares | ||||||||
| Net cash provided by financing activities | ||||||||
| Net change in cash, cash equivalents and restricted cash | ( | ) | ||||||
| Cash, cash equivalents and restricted cash, beginning of period | ||||||||
| Cash, cash equivalents and restricted cash, end of period | $ | $ | ||||||
| Supplemental disclosure of cash flow information: | ||||||||
| Cash paid for interest | $ | $ | ||||||
| Cash paid for income taxes | ||||||||
| Non-cash investing and financing activities: | ||||||||
| Debt issuance costs accrued in connection with notes payable | $ | $ | ||||||
| Common stock issued in settlement of shares committed for issuance | ||||||||
| Conversion of convertible notes into common stock | ||||||||
| Equity securities received on deconsolidation of subsidiary | ||||||||
| Reconciliation of cash, cash equivalents and restricted cash: | ||||||||
| Cash and cash equivalents | $ | $ | ||||||
| Restricted cash | ||||||||
| Total cash, cash equivalents and restricted cash | $ | $ | ||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
| F-4 |
Apimeds Pharmaceuticals US, Inc.
Notes to the Unaudited Condensed Consolidated Financial Statements
NOTE 1 — DESCRIPTION OF BUSINESS
Apimeds Pharmaceuticals US, Inc. (“APUS” or the “Company”) is incorporated in Delaware as a C-Corporation. On
MindWave and its subsidiaries hold and transact in digital assets and constitute the Company’s Digital Asset segment. The acquisition was accounted for as an asset acquisition under ASC 805-50 because substantially all of the fair value of the gross assets acquired was concentrated in a group of similar identifiable assets and the acquired set did not constitute a business. The Company was the accounting acquirer. Consideration consisted of
Until July 14, 2026, the Company operated its biopharmaceutical business through Lokahi. As of September 30, 2026, the corporate structure includes:
| ● | Apimeds Pharmaceuticals US, Inc.: public parent and SEC registrant, a Delaware C-Corporation. | |
| ● | MindWave Innovations Inc.: acquired December 1, 2025, wholly owned subsidiary, operates the Digital Asset segment. | |
| ● | Nexus Global Partners Inc.: incorporated during the three months ended June 30, 2026 in connection with the Settlement Agreement; is contemplated as a Newco established in connection with the separation of the BioBusiness and shall serve as the entity through which residual BioBusiness operations are continued, including the retention, development, licensing and commercialization of the BioBusiness and related intellectual property, to preserve and grow the value of the Company’s BioBusiness assets. As of September 30, 2026, Nexus had no assets or liabilities and had not conducted any BioBusiness operations; the BioBusiness was retained by Lokahi and is presented as a discontinued operation. |
On April 24, 2026, the Company, MindWave and Lokahi entered into a Confidential Settlement Agreement and Mutual Release (the “Settlement Agreement”) with Inscobee Inc. (now FreeT Inc.) and Apimeds Inc. (Korea), together with a related side letter, which provided for the separation of the BioBusiness. Under the Settlement Agreement, the Company agreed to transfer
On July 14, 2026, a subsidiary of Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack”) merged into Lokahi, with Lokahi surviving as a wholly owned subsidiary of Glucotrack. In the merger the Company’s remaining
On August 19, 2026, the Company entered into an Assignment and Transfer Agreement of Certain Apitox Rights with FreeT Inc. (“FreeT”), formerly Inscobee Inc., under which FreeT assigned to the Company
| F-5 |
Following the disposal of Lokahi, the Company’s continuing operations consist of its Digital Asset segment and corporate activities. MindWave operates as a blockchain and digital asset technology business and has been generating realized gains, trading gains, and digital asset yield income. In addition to holding, sale and conversion of digital assets, MindWave is developing commercial blockchain and technology applications, including initiatives intended to establish recurring revenue opportunities and expand its U.S. commercial presence. In September 2026, MindWave entered into technology services agreements with AQUAE Holdings Pte. Ltd. and Flash Sports & Media Holdings, Inc.
The Company’s digital asset activities are limited to the holding, sale and conversion of tokens acquired in the MindWave transaction; the Company is not a broker-dealer, exchange or investment company, has not committed to a plan to sell any specific holding, and has not classified any digital asset as held for sale. Consistent with the presentation in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, digital assets are therefore classified as non-current under ASC 210-10-45-1. Sales made to fund operating requirements, including those contemplated by management’s plans described in the going-concern discussion in Note 2, are effected from time to time out of that non-current position and do not, individually or in the aggregate, represent a plan to dispose of the holdings.
NOTE 2 — BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included. The results of operations for the three and nine months ended September 30, 2026 are not necessarily indicative of the results to be expected for the full year or any future period. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and related notes for the year ended December 31, 2025 included in the Company’s Annual Report on Form 10-K.
Reverse Stock Split
On or about July 23, 2026, the Company filed a certificate of amendment to its certificate of incorporation to effect a
Principals of Consolidation
The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, MindWave Innovations Inc. and its subsidiaries and Nexus Global Partners Inc., and the accounts of Lokahi Therapeutics Inc. through July 14, 2026, the date of deconsolidation, measured using its June 30, 2026 balances (see Note 3). All significant intercompany accounts and transactions have been eliminated in consolidation.
Liquidity
The Company has incurred recurring losses from operations and negative cash flows from operating activities. For the nine months ended September 30, 2026 the Company incurred a net loss of $
| F-6 |
Use of Estimates
The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. Significant estimates include the fair value of digital assets (in particular the NILA token), the fair value of the Company’s investment in Glucotrack, the fair value of the embedded conversion feature accounted for as a derivative liability, the effective interest rates used to accrete debt discounts, the incremental borrowing rate used to measure lease liabilities, and the valuation of share-based payments. Actual results could differ from those estimates.
Digital Assets
The Company accounts for its holdings of crypto assets in accordance with ASC 350-60, Intangibles — Goodwill and Other — Crypto Assets, as amended by ASU 2023-08. Crypto assets within the scope of ASC 350-60 are measured at fair value at each reporting date, with changes in fair value recognized in the condensed consolidated statements of operations as unrealized gains or losses. Gains and losses realized on sales are determined on a specific-identification basis and are presented separately. Digital assets held for market-making activity, and the corresponding costs of those activities, are presented net within trading gains, net. Digital assets received under the Company’s digital asset yield arrangements are recognized at fair value on the date of receipt, presented within revenue as digital asset yield income (see Note 4), and are thereafter measured at fair value under ASC 350-60.
The Company’s digital assets consisted of the following:
| Units held September 30, 2026 | Fair value September 30, 2026 | Units held December 31, 2025 | Fair value December 31, 2025 | |||||||||||||
| Bitcoin | $ | $ | ||||||||||||||
| NILA tokens | ||||||||||||||||
| Tether (USDT) | ||||||||||||||||
| Other exchange wallet balances | ||||||||||||||||
| Total digital assets, at fair value | $ | $ | ||||||||||||||
Other exchange wallet balances represent residual quantities of various tokens held in the Company’s accounts at digital-asset exchanges, none of which is individually material. The quoted price of the NILA Tokens declined from $
During the three and nine months ended September 30, 2026 the Company received
| Nine months ended September 30, 2026 | ||||
| Balance at December 31, 2025 | $ | |||
| Additions — USDT received from sales of NILA Tokens | ||||
| Additions — BTC acquired in exchange for USDT | ||||
| Dispositions — NILA Tokens sold for USDT | ( | ) | ||
| Dispositions — NILA Tokens delivered in payment for services | ( | ) | ||
| Dispositions — USDT exchanged for BTC | ( | ) | ||
| Dispositions — USDT paid for fees on sales of NILA Tokens | ( | ) | ||
| Other, net | ||||
| Digital assets received as yield income | ||||
| Realized gain on sale of digital assets | ||||
| Trading gains, net | ||||
| Unrealized gain (loss) from changes in fair value | ( | ) | ||
| Balance at September 30, 2026 | $ | |||
| F-7 |
| Three months ended September 30, 2026 | Nine months ended September 30, 2026 | |||||||
| Unrealized gain (loss) from changes in fair value of digital assets | $ | $ | ( | ) | ||||
| Realized gain on sale of digital assets | ||||||||
| Trading gains, net | ( | ) | ||||||
| Digital asset yield income | ||||||||
| Net gain (loss) recognized on digital assets | $ | $ | ( | ) | ||||
There were digital assets pledged as collateral as of September 30, 2026 or December 31, 2025, and there were restrictions on the sale of the Company’s digital assets other than market liquidity. The carrying amount of digital assets decreased by $
Fair Value Measurement
ASC 820, Fair Value Measurement, establishes a three-level hierarchy that prioritizes the inputs used to measure fair value: Level 1 — quoted prices in active markets for identical assets or liabilities; Level 2 — observable inputs other than Level 1 prices, including quoted prices for similar assets or liabilities or quoted prices in markets that are not active; and Level 3 — unobservable inputs supported by little or no market activity. Bitcoin and Tether are measured using quoted prices from principal active exchange markets and are classified within Level 1. The NILA token trades in markets that are not active for the size of the Company’s position; its fair value is measured using observable quoted transaction prices for the token and is classified within Level 2. The derivative liability arising from the embedded conversion feature of the Company’s convertible note is measured using a Monte Carlo simulation and is classified within Level 3. Consistent with the determination made as of December 31, 2025, the limited number of trading venues on which the NILA token trades and its daily trading volume relative to the size of the Company’s position indicate that the market for the token does not meet the active market threshold required for Level 1 classification; the exchange-quoted prices used are observable inputs corroborated by transaction data. The Company’s investment in Glucotrack common stock is measured using the quoted closing price on Nasdaq and is classified within Level 1. The Glucotrack Series A preferred stock, which is not traded and had not been issued to the Company as of September 30, 2026, is measured on an as-converted basis using the quoted price of Glucotrack common stock and is classified within Level 2.
Assets and liabilities measured at fair value on a recurring basis were as follows:
| September 30, 2026 | ||||||||||||||||
| Level 1 | Level 2 | Level 3 | Total | |||||||||||||
| Assets: | ||||||||||||||||
| Bitcoin | $ | $ | $ | $ | ||||||||||||
| Other exchange wallet balances | ||||||||||||||||
| NILA tokens | ||||||||||||||||
| Investment in Glucotrack, Inc. — common stock | ||||||||||||||||
| Investment in Glucotrack, Inc. — Series A preferred stock | ||||||||||||||||
| Total assets at fair value | $ | $ | $ | $ | ||||||||||||
| Liabilities: | ||||||||||||||||
| Derivative liability — embedded conversion feature | $ | $ | $ | $ | ||||||||||||
| F-8 |
| December 31, 2025 | Level 1 | Level 2 | Level 3 | Total | ||||||||||||
| Bitcoin | $ | $ | ||||||||||||||
| NILA tokens | ||||||||||||||||
| Tether (USDT) | ||||||||||||||||
| Other exchange wallet balances | ||||||||||||||||
| Total assets at fair value | ||||||||||||||||
| Derivative liability — embedded conversion feature | ||||||||||||||||
| Total liabilities at fair value | $ | $ | ||||||||||||||
The following table presents the changes in the Level 3 derivative liability:
| Derivative liability | ||||
| Balance at December 31, 2025 | $ | |||
| Change in fair value — three months ended March 31, 2026 | ( | ) | ||
| Balance at March 31, 2026 | ||||
| Change in fair value — three months ended June 30, 2026 | ( | ) | ||
| Balance at June 30, 2026 | $ | |||
| Change in fair value — three months ended September 30, 2026 | ( | ) | ||
| Reclassification to additional paid-in capital upon conversion of notes | ( | ) | ||
| Balance at September 30, 2026 | $ | |||
Other than the reclassification of $
The significant unobservable inputs used in the Monte Carlo simulation of the derivative liability as of September 30, 2026 were a share price of $
Other exchange wallet balances of $
The carrying amounts of cash and cash equivalents, restricted cash, other current assets, accounts payable and accrued expenses and advances payable approximate fair value because of the short-term nature of these instruments.
| F-9 |
Convertible Instruments
The Company evaluates the terms of its convertible instruments to determine whether any embedded features require bifurcation and separate accounting as derivatives under ASC 815. The embedded conversion feature of the Company’s senior secured convertible note was determined to require bifurcation and is carried at fair value, with changes in fair value recognized in the condensed consolidated statements of operations. The resulting discount, together with original issue discounts and issuance costs, is accreted to interest expense over the term of the instrument using the effective interest method.
Discontinued Operations
A component of the Company that has been disposed of is reported as a discontinued operation when the disposal represents a strategic shift that has, or will have, a major effect on the Company’s operations and financial results, in accordance with ASC 205-20. The results of discontinued operations, including any gain or loss on disposal, are presented separately from continuing operations for all periods presented, and the assets and liabilities of the discontinued operation are presented separately on the condensed consolidated balance sheet for each comparative period. General corporate overhead is not allocated to discontinued operations. Interest on debt that is an obligation of the disposed component is included in discontinued operations. Gains and losses on the deconsolidation of a subsidiary are measured in accordance with ASC 810-10-40 as the fair value of consideration received less the carrying amount of the former subsidiary’s net assets (liabilities). See Note 3.
Revenue Recognition
The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers, when control of promised goods or services transfers to a customer, in an amount that reflects the consideration to which the Company expects to be entitled. Revenue from software development and deployment services is recognized when the developed software is delivered to and accepted by the customer, which is when the Company’s performance obligation is satisfied. Invoices under the Company’s agreements are generally payable within 90 days; the Company does not adjust the consideration for a significant financing component when the period between transfer and payment is one year or less. Contract liabilities represent amounts invoiced or due before the related performance obligations are satisfied. Cost of revenue consists of the salaries of personnel and the development costs directly attributable to delivering software development and deployment services, and is expensed as incurred.
Digital Asset Yield Income. Digital asset yield income consists of bitcoin received under the Company’s digital asset yield arrangement. It is outside the scope of ASC 606 and is recognized when the bitcoin are received, measured at fair value. Beginning with the three months ended September 30, 2026, the Company presents digital asset yield income within revenue because generating yield on its bitcoin holdings is one of its principal ongoing activities. Digital asset yield income of $
Accounts Receivable
Accounts receivable are recorded at the invoiced amount and do not bear interest. The Company measures expected credit losses on accounts receivable under ASC 326, Financial Instruments — Credit Losses, considering the customer’s credit quality, the aging of balances, current conditions and reasonable and supportable forecasts. No allowance for credit losses was recorded as of September 30, 2026.
| F-10 |
Investment in Equity Securities
Equity securities with readily determinable fair values over which the Company does not have significant influence are measured at fair value in accordance with ASC 321, with changes in fair value recognized in the condensed consolidated statements of operations. The Company’s investment in Glucotrack is accounted for under this policy. See Note 5.
Concentrations of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash, restricted cash and digital assets. The Company maintains cash balances at financial institutions in the United States, Singapore and the United Arab Emirates, which at times may exceed federally insured limits. As of September 30, 2026, digital assets of $
Segment Information
Following the disposal of Lokahi, the Company operates in one reportable segment, the Digital Asset segment, which comprises the digital-asset holding and trading operations and blockchain technology activities conducted through MindWave and its subsidiaries. The BioBusiness segment, which comprised the clinical-stage pharmaceutical operations conducted through Lokahi, is presented as a discontinued operation for all periods presented (see Note 3) and is excluded from the segment information below. Corporate consists of holding-company activities, including the Company’s convertible note, derivative liability, restricted cash and investment in Glucotrack.
Three months ended September 30, 2026:
| Digital Asset | Corporate | Consolidated | ||||||||||
| Revenue: | ||||||||||||
| Software development and deployment services | $ | $ | $ | |||||||||
| Digital asset yield income | ||||||||||||
| Total revenue | ||||||||||||
| Cost of revenue | ||||||||||||
| General and administrative | ||||||||||||
| Income (loss) from operations | ( | ) | ||||||||||
| Unrealized gain (loss) from changes in fair value of digital assets | ||||||||||||
| Realized gain on sale of digital assets | ||||||||||||
| Trading gains, net | ( | ) | ( | ) | ||||||||
| Foreign currency gains (losses), net | ( | ) | ( | ) | ||||||||
| Change in fair value of equity securities | ( | ) | ( | ) | ||||||||
| Change in fair value of derivative liability | ||||||||||||
| Interest income | ||||||||||||
| Interest expense | ( | ) | ( | ) | ||||||||
| Total other income (expense), net | ( | ) | ||||||||||
| Income (loss) from continuing operations | $ | $ | ( | ) | $ | |||||||
| F-11 |
Nine months ended September 30, 2026:
| Digital Asset | Corporate | Consolidated | ||||||||||
| Revenue: | ||||||||||||
| Software development and deployment services | $ | $ | $ | |||||||||
| Digital asset yield income | ||||||||||||
| Total revenue | ||||||||||||
| Cost of revenue | ||||||||||||
| General and administrative | ||||||||||||
| Income (loss) from operations | ( | ) | ( | ) | ( | ) | ||||||
| Unrealized gain (loss) from changes in fair value of digital assets | ( | ) | ( | ) | ||||||||
| Realized gain on sale of digital assets | ||||||||||||
| Trading gains, net | ||||||||||||
| Foreign currency gains (losses), net | ( | ) | ( | ) | ||||||||
| Change in fair value of equity securities | ( | ) | ( | ) | ||||||||
| Change in fair value of derivative liability | ||||||||||||
| Interest income | ||||||||||||
| Interest expense | ( | ) | ( | ) | ||||||||
| Total other income (expense), net | ( | ) | ( | ) | ( | ) | ||||||
| Income (loss) from continuing operations | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
Total assets by segment were as follows:
| September 30, 2026 | December 31, 2025 | |||||||
| Digital Asset | $ | $ | ||||||
| Corporate | ||||||||
| Assets of discontinued operations | ||||||||
| Total assets | $ | $ | ||||||
Assets of the BioBusiness as of December 31, 2025 are presented as assets of discontinued operations.
For the three and nine months ended September 30, 2025, the Company’s continuing operations consisted of corporate activities only; all operating expenses of those periods related to the BioBusiness and are presented in discontinued operations.
Cash, Cash Equivalents and Restricted Cash
The Company considers all highly liquid instruments with an original maturity of three months or less at the date of purchase to be cash equivalents. Restricted cash of $
Leases
The Company determines whether an arrangement is or contains a lease at inception. Operating leases with terms in excess of twelve months are recognized on the condensed consolidated balance sheet as a right-of-use asset and a corresponding lease liability, measured at the present value of the remaining lease payments using the Company’s incremental borrowing rate, because the rate implicit in the lease is not readily determinable. Lease cost is recognized on a straight-line basis over the lease term. See Note 13.
| F-12 |
Property and Equipment, net
Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally three years for computer equipment and five years for furniture and fixtures. Effective February 28, 2026, the Company increased its capitalization threshold from $
Property and equipment as of December 31, 2025 related to Lokahi and is presented within noncurrent assets of discontinued operations. Depreciation of $
Related Parties
The Company follows ASC 850, Related Party Disclosures, under which a party is considered related if it directly or indirectly controls, is controlled by, or is under common control with the Company, or if it has the ability to exercise significant influence over the Company in making financial or operating decisions. See Note 11.
General and Administrative
General and administrative expenses consist principally of salaries, benefits and share-based compensation for administrative personnel, professional and consulting fees, insurance, investor relations and other public-company costs, transaction and advisory fees, and facility costs. Advertising costs are expensed as incurred and were not material in any period presented.
Research and Development
Research and development costs are expensed as incurred and consist principally of salaries, benefits and share-based compensation for research personnel, contract research organization fees, clinical trial costs, non-clinical study costs, manufacturing of clinical supply, and professional consulting fees. Payments made in advance of the receipt of the related goods or services are capitalized as prepaid development costs and expensed as the goods are received or the services are performed.
Stock-Based Compensation
The Company measures share-based awards granted to employees, directors and non-employees at the grant-date fair value and recognizes the resulting expense on a straight-line basis over the requisite service period. The fair value of stock options is estimated using the Black-Scholes option-pricing model. Forfeitures are recognized as they occur. See Note 10.
Income Taxes
The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial statement and tax bases of assets and liabilities, measured using enacted tax rates expected to apply in the periods in which those temporary differences are expected to reverse. A valuation allowance is recorded when it is more likely than not that some or all of the deferred tax assets will not be realized. See Note 12.
| F-13 |
Net Income (Loss) per Share
Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding during the period, including shares committed for issuance for no further consideration. Diluted net income (loss) per share is computed by dividing net income (loss), adjusted for the effect of dilutive convertible instruments, by the weighted-average number of common shares and dilutive potential common shares outstanding, using income (loss) from continuing operations as the control number.
For the three months ended September 30, 2026, the Company reported income from continuing operations, and diluted net income per share includes the shares issuable upon conversion of the senior secured convertible note under the if-converted method:
For the nine months ended September 30, 2026 the Company reported a loss from continuing operations, and for the 2025 periods the effect of potentially dilutive securities was anti-dilutive; accordingly, diluted net income (loss) per share equals basic net income (loss) per share for those periods.
All share and per-share amounts have been retroactively adjusted for the
The following potentially dilutive securities were excluded from the computation of diluted net income (loss) per share for all periods presented:
| September 30, 2026 | September 30, 2025 | |||||||
| Shares issuable upon conversion of Series A convertible preferred stock | ||||||||
| Stock options outstanding | ||||||||
| Warrants outstanding | ||||||||
| Total | ||||||||
The Series A Convertible Preferred Stock is excluded because its conversion is subject to NYSE American approval of the Company’s listing application and had not occurred as of September 30, 2026. Stock options and warrants are excluded because their exercise prices exceeded the average market price of the Company’s common stock. For the nine months ended September 30, 2026 and the 2025 periods, shares issuable upon conversion of the senior secured convertible note were also excluded because their effect would have been anti-dilutive.
Emerging Growth Company
The Company is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) and has elected to use the extended transition period afforded by Section 107(b) of the JOBS Act for complying with new or revised accounting standards. As a result, the Company’s financial statements may not be comparable to those of companies that comply with public-company effective dates. The Company is also a “smaller reporting company” as defined in Rule 12b-2 under the Exchange Act.
Recently Issued Accounting Pronouncements
In December 2023, the FASB issued ASU 2023-08, Accounting for and Disclosure of Crypto Assets, which the Company has adopted and applied to its digital-asset holdings. In November 2023, the FASB issued ASU 2023-07, Segment Reporting — Improvements to Reportable Segment Disclosures, which the Company has adopted. In December 2023, the FASB issued ASU 2023-09, Income Taxes — Improvements to Income Tax Disclosures, effective for annual periods beginning after December 15, 2024, and in November 2024 the FASB issued ASU 2024-03, Income Statement — Reporting Comprehensive Income — Expense Disaggregation Disclosures, effective for annual periods beginning after December 15, 2026. The Company is evaluating the effect of ASU 2024-03 on its disclosures. Management does not believe that any other recently issued but not yet effective accounting pronouncements would have a material effect on the condensed consolidated financial statements.
| F-14 |
In November 2024, the FASB issued ASU 2024-04, Debt — Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments, effective for annual periods beginning after December 15, 2025 and interim periods within those annual periods. The Company adopted ASU 2024-04 on January 1, 2026. The conversions of the senior secured convertible note during the three months ended September 30, 2026 were made under the original conversion terms and were not induced conversions; adoption had no effect.
In July 2025, the FASB issued ASU 2025-05, Financial Instruments — Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets, which provides a practical expedient to assume that current conditions as of the balance sheet date do not change for the remaining life of current accounts receivable and current contract assets arising from transactions under ASC 606. The ASU is effective for annual periods beginning after December 15, 2025 and interim periods within those annual periods. The Company has not elected the practical expedient.
In September 2025, the FASB issued ASU 2025-06, Intangibles — Goodwill and Other — Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software, which removes the project-stage model and requires capitalization to begin when management has authorized and committed to funding the software project and it is probable that the project will be completed and the software used to perform its intended function. The ASU is effective for annual periods beginning after December 15, 2027 and interim periods within those annual periods, with early adoption permitted. The Company is evaluating the effect of the ASU on the accounting for its platform development costs.
NOTE 3 — DECONSOLIDATION OF LOKAHI AND DISCONTINUED OPERATIONS
As described in Note 1,
| Amount | ||||
| Fair value of Glucotrack common stock received ( | $ | |||
| Fair value of Glucotrack Series A preferred stock to be received ( | ||||
| Total fair value of consideration received | ||||
| Carrying amount of Lokahi net liabilities derecognized | ||||
| Gain on deconsolidation of Lokahi | $ | |||
The Glucotrack securities were measured using Glucotrack’s closing price of $
Lokahi conducted the Company’s BioBusiness segment, which was the Company’s entire biopharmaceutical business and its only operating business before the acquisition of MindWave on December 1, 2025. The disposal represents a strategic shift that has a major effect on the Company’s operations and financial results, and the results of Lokahi are presented as discontinued operations for all periods presented. General corporate overhead has not been allocated to discontinued operations. Interest on Lokahi’s notes payable, which were obligations of Lokahi, is included in discontinued operations. The comparative 2025 periods are presented on the basis used in the segment disclosure in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, under which all operating expenses before December 1, 2025 were attributed to the BioBusiness; the change in fair value of the warrant liability, interest income and interest expense for those periods remain in continuing operations.
| F-15 |
The results of discontinued operations were as follows:
| Three months ended September 30, 2026 | Nine months ended September 30, 2026 | Three months ended September 30, 2025 | Nine months ended September 30, 2025 | |||||||||||||
| Research and development | $ | $ | $ | $ | ||||||||||||
| General and administrative | ( | ) | ||||||||||||||
| Interest expense | ||||||||||||||||
| Interest income | ( | ) | ||||||||||||||
| Income (loss) from operations of Lokahi | ( | ) | ( | ) | ( | ) | ||||||||||
| Gain on deconsolidation of Lokahi | ||||||||||||||||
| Income (loss) from discontinued operations | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||
Lokahi’s results for the six months ended June 30, 2026 include $
The assets and liabilities of discontinued operations as of December 31, 2025 were as follows. There were no assets or liabilities of discontinued operations as of September 30, 2026.
| December 31, 2025 | ||||
| Cash and cash equivalents | $ | |||
| Short-term investments | ||||
| Prepaid expenses | ||||
| Current assets of discontinued operations | ||||
| Long-term prepaid expenses | ||||
| Property and equipment, net | ||||
| Operating lease right-of-use asset, net | ||||
| Noncurrent assets of discontinued operations | ||||
| Total assets of discontinued operations | $ | |||
| Accounts payable and accrued expenses | $ | |||
| Accrued interest | ||||
| Notes payable — related party | ||||
| Operating lease liability, current | ||||
| Current liabilities of discontinued operations | ||||
| Operating lease liability, net of current portion (noncurrent liabilities of discontinued operations) | ||||
| Total liabilities of discontinued operations | $ | |||
The Company presents the cash flows of discontinued operations combined with those of continuing operations in the condensed consolidated statements of cash flows. Cash of Lokahi of $
| Nine months ended September 30, 2026 | Nine months ended September 30, 2025 | |||||||
| Depreciation of property and equipment | $ | $ | ||||||
| Amortization of operating lease right-of-use asset | ||||||||
| Stock-based compensation | ||||||||
| Reversal of stock-based compensation on forfeited options | ( | ) | ||||||
| Accretion of debt discount — Lokahi notes payable | ||||||||
| Non-cash interest accrued — Lokahi notes payable | ||||||||
| Gain on deconsolidation of Lokahi | ( | ) | ||||||
| Capital expenditures | ||||||||
| Non-cash investing activity — Glucotrack securities received | ||||||||
| F-16 |
After the disposal, the Company’s continuing involvement with Lokahi consists of its investment in Glucotrack (Note 5), the Apitox royalty and revenue participation rights assigned by FreeT (Note 1), the San Diego office lease, which remains in the Company’s name (Note 13), and stock options of the Company held by former employees and consultants of Lokahi (Note 10).
License agreements. The Company’s license and supply arrangements with Apimeds, Inc. (Korea), a related party, relating to APITOX were part of the BioBusiness and are included in discontinued operations through the deconsolidation of Lokahi. No milestone payments became due and no royalty obligations were incurred during the three and nine months ended September 30, 2026 or 2025. After the disposal, the Company’s rights relating to Apitox consist of the royalty and revenue participation rights assigned by FreeT described in Note 1. Refer to the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 for a description of the material terms of the license agreements.
NOTE 4 — REVENUE
The Company’s revenue for the three and nine months ended September 30, 2026 consisted of software development and deployment services provided by TechyTrade FZ-LLC, a subsidiary in the Digital Asset segment, to two customers under agreements entered into in July 2026. Revenue was recognized at a point in time, when the developed software was delivered to and accepted by the customer. Invoices are payable 90 days from the invoice date, and no amounts had been collected as of September 30, 2026.
Digital asset yield income. Effective April 1, 2026, TechyTrade FZ-LLC appointed Calfin Capital Pte Ltd as discretionary investment manager for a portion of its bitcoin holdings under an investment management agreement with a term of one year, expiring March 31, 2027, which either party may terminate on 60 days’ notice. The investment manager may deploy the managed assets in trading and yield-generation strategies, including spot and derivatives trading, staking, liquidity provision and arbitrage. The managed assets remain in accounts and wallets held by TechyTrade FZ-LLC, which retains custody and the private keys; the investment manager has trading access only and may not withdraw, transfer or pledge the assets. The agreement provides no guaranteed return, and the Company bears the risk of loss on the managed assets. The investment manager is entitled to an annual management fee of
Contract balances were as follows:
| September 30, 2026 | December 31, 2025 | |||||||
| Accounts receivable | $ | $ | ||||||
| Accounts receivable — related party | ||||||||
| Contract liability — related party | $ | $ | ||||||
No revenue was recognized during the period from amounts included in contract liabilities. The contract liability relates to the upfront installment under the Company’s agreement with AQUAE Holdings Pte. Ltd., a related party (see Note 11).
Remaining performance obligations. As of September 30, 2026, the transaction price allocated to remaining performance obligations comprised fees of $
NOTE 5 — INVESTMENT IN EQUITY SECURITIES
The Company’s investment in Glucotrack consists of
| Investment in Glucotrack | ||||
| Fair value at July 14, 2026 | $ | |||
| Change in fair value — three months ended September 30, 2026 | ( | ) | ||
| Balance at September 30, 2026 | $ | |||
The fair value as of September 30, 2026 is based on Glucotrack’s closing price of $
| F-17 |
NOTE 6 — PREPAID EXPENSE AND OTHER ASSETS
Other current assets of $
NOTE 7 — ACCOUNTS PAYABLE AND ACCRUED EXPENSES
Accounts payable and accrued expenses consisted of the following:
| September 30, 2026 | December 31, 2025 | |||||||
| Trade accounts payable | ||||||||
| Accrued compensation | ||||||||
| Other accrued expenses | ||||||||
| Total accounts payable and accrued expenses | $ | $ | ||||||
Legal and consulting fees of $
In addition to the amounts above, the Company had accrued offering costs of $
NOTE 8 — DEBT
Convertible notes, net
In 2025 the Company issued a senior secured convertible note with an aggregate redemption amount of $
| September 30, 2026 | December 31, 2025 | |||||||
| Convertible note, principal recorded by the parent | $ | $ | ||||||
| Less: unamortized debt issuance costs | ( | ) | ( | ) | ||||
| Less: unamortized original issue discount | ( | ) | ( | ) | ||||
| Less: unamortized derivative discount | ( | ) | ( | ) | ||||
| Senior secured convertible note, net | ||||||||
| Convertible note, principal recorded by subsidiary | ||||||||
| Total convertible notes, net | $ | $ | ||||||
| F-18 |
Accretion of the discounts on the senior secured convertible note was $
Conversions. On September 24, 2026, the holder delivered notices to convert an aggregate of $
Forbearance and third-party settlement. The holder of the senior secured convertible note had delivered a notice of default under the financing documents and, under a forbearance agreement entered into on April 30, 2026 and disclosed in the Company’s Current Report on Form 8-K filed May 4, 2026, agreed to forbear from exercising remedies through June 30, 2026. The forbearance period expired on June 30, 2026 and was not extended. On September 4, 2026, Glucotrack, Lokahi, Erik Emerson and RXRR Capital Partners LLC entered into a settlement agreement with the holder resolving disputes regarding the indebtedness owed to the holder by the Company, under which those parties are jointly and severally obligated to pay the holder $
Notes payable, net
During the six months ended June 30, 2026, Lokahi issued four short-term notes payable with an aggregate principal amount of $
| Note | Issue date | Maturity | Principal | Original issue discount | Issuance costs | Flat interest | ||||||||||||||
| Note 1 | $ | $ | $ | $ | ||||||||||||||||
| Note 2 | ||||||||||||||||||||
| Note 3 | ||||||||||||||||||||
| Note 4 | ||||||||||||||||||||
| Total | $ | $ | $ | $ | ||||||||||||||||
Note 1 was repaid in full on May 5, 2026 for $
Cash proceeds from the notes payable were $
| F-19 |
Interest expense
Interest expense presented in continuing operations consists principally of accretion of the discounts on the senior secured convertible note. Interest expense of Lokahi of $
Accrued interest of $
NOTE 9 — SHAREHOLDERS’ EQUITY
Reverse Stock Split
On or about July 23, 2026, the Company filed a certificate of amendment to its certificate of incorporation to effect a 1-for-10 reverse stock split of its issued and outstanding shares of common stock and preferred stock, which became effective at 12:01 a.m. Eastern Time on July 24, 2026. The same certificate of amendment reduced the par value per share of the common stock and the preferred stock from $
Preferred Stock
The Company is authorized to issue
Common Stock
The Company is authorized to issue
Advisory Shares
On February 2, 2026, the Company’s board approved the issuance of
| F-20 |
Warrants
As of September 30, 2026 and December 31, 2025,
Subscription Receivable
During the three months ended June 30, 2026, the Company collected $
Dividends
The Company has not declared or paid any dividends on its common stock and does not anticipate doing so in the foreseeable future.
NOTE 10 — STOCK-BASED COMPENSATION
The Company maintains the 2024 Equity Incentive Plan (the “2024 Plan”), under which
Stock option activity for the nine months ended September 30, 2026 was as follows:
| Number of options | Weighted-average exercise price | Weighted-average remaining contractual term (years) | ||||||||||
| Outstanding at December 31, 2025 | $ | |||||||||||
| Granted | ||||||||||||
| Exercised | ||||||||||||
| Forfeited | ) | |||||||||||
| Outstanding at September 30, 2026 | $ | |||||||||||
All share and per-share amounts above have been adjusted for the
| F-21 |
Stock-based compensation expense was recorded as follows:
| Three months ended September 30, 2026 | Three months ended September 30, 2025 | Nine months ended September 30, 2026 | Nine months ended September 30, 2025 | |||||||||||||
| General and administrative | $ | $ | $ | $ | ||||||||||||
The amounts above exclude the $
NOTE 11 — RELATED PARTY TRANSACTIONS
Advance payable to related party of $
Notes payable — related party consisted of the following:
| Holder | Interest rate | Maturity | September 30, 2026 | December 31, 2025 | ||||||||||
| Inscobee, Inc. | % | $ | $ | |||||||||||
| Inscobee, Inc. | % | |||||||||||||
| Apimeds, Inc. (Korea) | % | |||||||||||||
| Other | — | |||||||||||||
| Total notes payable — related party | $ | $ | ||||||||||||
Under the Settlement Agreement described in Note 1, Lokahi assumed the notes payable — related party of $
Related-party compensation expense was $
Inscobee, Inc. is a beneficial owner of more than
As of September 30, 2026, $
On September 14, 2026, MindWave entered into a 12-month software development and technology services agreement with AQUAE Holdings Pte. Ltd., under which MindWave will design, develop and support a platform for the issuance, verification, transfer and retirement of ALCI environmental credits. Consideration comprises fees of $
| F-22 |
FreeT Inc., formerly Inscobee, Inc., assigned to the Company the Apitox rights described in Note 1 on August 19, 2026, with no monetary consideration specified. In addition, Erik Emerson, an executive of Lokahi who holds options to purchase the Company’s common stock, became Chief Executive Officer and a director of Glucotrack in connection with the merger described in Note 1.
Correction of prior-period disclosure. Amounts owed by related parties of $
NOTE 12 — INCOME TAXES
The Company recorded provision for or benefit from income taxes for the three and nine months ended September 30, 2026 or 2025. The Company has incurred net operating losses since inception and maintains a full valuation allowance against its net deferred tax assets, as management has concluded that it is more likely than not that those assets will not be realized. Accordingly, the Company’s effective tax rate differs from the U.S. federal statutory rate of
The Company has unrecognized tax benefits and has recorded interest or penalties related to uncertain tax positions as of September 30, 2026 or December 31, 2025.
NOTE 13 — COMMITMENTS AND CONTINGENCIES
Operating lease
The Company is the lessee under an operating lease for office space in San Diego, California that commenced on January 1, 2026 and expires on December 31, 2028. The lease was contributed to Lokahi under an executed contribution agreement, and the related right-of-use asset and lease liability were derecognized on the deconsolidation of Lokahi (see Note 3). The lease remains in the Company’s name, the Company has not been released by the landlord, and the Company could be required to make the remaining payments if Lokahi does not. No liability has been recognized for this obligation. Remaining undiscounted payments under the lease were $
Settlement Agreement
Under the Settlement Agreement described in Note 1, Nexus Global Partners Inc., a wholly owned subsidiary of the Company, is entitled to
Platform Development Agreement
On July 17, 2026, MindWave Innovations Inc. entered into a Master Services Agreement with Digital Prizm Pte Ltd for the development of a technology platform for total consideration of $
| F-23 |
NYSE American continued listing
On April 17, 2026, the Company received notice from NYSE American that it was not in compliance with Section 1007 of the NYSE American Company Guide as a result of its failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2025. The Company was granted an initial cure period of six months, expiring October 15, 2026, which the exchange may extend by up to an additional six months, and its common stock trades under the symbol “APUS.LF” pending regained compliance. Trading in the Company’s common stock was halted on April 2, 2026 and, as disclosed in the Company’s Current Report on Form 8-K filed April 22, 2026, remained halted as of that date. Trading had resumed before June 30, 2026, and the common stock has traded on a split-adjusted basis under the symbol “APUS.LF” since July 24, 2026. The Company filed its Annual Report on Form 10-K for the year ended December 31, 2025 on May 4, 2026 and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 on May 26, 2026, in each case after the applicable due date, and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 on August 14, 2026. Under Section 1007, the Company will regain compliance only when it is current in all of its required periodic filings with the SEC. There can be no assurance that the Company will regain compliance within the cure period.
Legal proceedings and other contingencies
From time to time the Company may become involved in legal proceedings arising in the ordinary course of business. Other than as described above, management is not aware of any pending or threatened legal proceedings that would be expected to have a material adverse effect on the Company’s financial position, results of operations or cash flows.
Class action. The Company is one of approximately 30 defendants, together with the underwriters of certain offerings, in a putative securities class action [caption, court and filing date to be confirmed with counsel]. The Company has referred the matter to its directors’ and officers’ liability insurance carrier and had received no communication from the plaintiffs as of September 15, 2026. The Company is unable to estimate the possible loss or range of loss, if any, and no amount has been accrued.
Management compensation. On September 30, 2026, the board of directors approved a management compensation schedule, with salaries effective from June 2026, subject to the completion of financing and the resolution of matters relating to the senior secured convertible note. Neither condition had been satisfied as of September 30, 2026, and no amount has been accrued.
NOTE 14 — SUBSEQUENT EVENTS
The Company has evaluated subsequent events through the date these condensed consolidated financial statements were issued.
Appointment of Chief Financial Officer. On September 30, 2026, the board of directors appointed Eric Sherb as Chief Financial Officer, principal financial officer and principal accounting officer, effective October 1, 2026, following the resignation of the Company’s Interim Chief Financial Officer effective September 29, 2026.
BlockAssure Master Service Agreement. On October 4, 2026, MindWave entered into a two-year Master Service Agreement with BlockAssure Inc., which renews automatically for one-year terms, under which MindWave will build, deploy, host and maintain a blockchain subnet for BlockAssure in exchange for a fixed development fee of $
Additional Financing. In October 2026, TechyTrade Innovations Pte. Ltd. received aggregate funding of $
The funding was received in two tranches consisting of $
| F-24 |
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis should be read together with our unaudited condensed consolidated financial statements and the related notes included in Item 1 of this Quarterly Report and our audited consolidated financial statements for the year ended December 31, 2025. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those discussed below. All share and per-share amounts have been retroactively adjusted for the 1-for-10 reverse stock split effected July 24, 2026.
Overview
We operate through one reportable segment, our Digital Asset segment, conducted through MindWave Innovations Inc. and its subsidiaries, which holds and transacts in digital assets, principally Bitcoin, Tether and NILA tokens, and is developing commercial blockchain and technology applications. Until July 14, 2026 we also conducted a clinical-stage pharmaceutical business through our subsidiary Lokahi Therapeutics Inc. (the BioBusiness), which is presented as a discontinued operation. As of September 30, 2026 we held digital assets with a fair value of $142,423,473, representing 93% of our total assets. Because those assets are measured at fair value with changes recognized in earnings, our reported results are subject to substantial period-to-period volatility that is unrelated to our operating performance.
On April 24, 2026 we entered into a Confidential Settlement Agreement and Mutual Release providing, among other things, for the transfer of 51% of the equity of Lokahi. On July 14, 2026 Lokahi became a wholly owned subsidiary of Glucotrack, Inc. in a merger in which we received Glucotrack common stock and the right to receive Glucotrack Series A preferred stock. We deconsolidated Lokahi using its June 30, 2026 balances and recognized a gain on deconsolidation of $7,803,653, which is included in income from discontinued operations. Our investment in Glucotrack is measured at fair value, and we recognized a loss of $710,705 on the investment in the three months ended September 30, 2026. On August 19, 2026 FreeT Inc. assigned to us certain Apitox royalty and revenue participation rights, with no monetary consideration specified.
In September 2026 MindWave entered into technology services agreements with AQUAE Holdings Pte. Ltd. and Flash Sports & Media Holdings, Inc., and on October 4, 2026 it entered into a two-year Master Service Agreement with BlockAssure Inc. These agreements provide for fees and, in each case, an allocation of 20% of the tokens issued on the platforms MindWave builds, and in the case of Flash Sports & Media Holdings, Inc., shares of its common stock.
Going Concern
We have incurred recurring losses and negative operating cash flows. We incurred a net loss of $21,586,816 for the nine months ended September 30, 2026, used $7,953,510 of cash in operating activities, and had an accumulated deficit of $31,979,877 and cash and cash equivalents of $17,912 as of September 30, 2026. In addition, a senior secured convertible note with outstanding principal of $10,475,000, maturing December 8, 2026, was a current obligation as of September 30, 2026, and a $2,480,000 payment due under a platform development agreement was unpaid and more than 30 days past due (see Note 13 to the condensed consolidated financial statements). These conditions raise substantial doubt about our ability to continue as a going concern, as further described in Note 2 to the condensed consolidated financial statements. Additional tranches under the Securities Purchase Agreement providing for the issuance of notes in tranches with an aggregate redemption amount of up to $120,900,000 are issuable only on satisfaction of the conditions in the agreement and at the holder’s election, and we have no unilateral right to draw; no further tranche has been drawn and the $10,900,000 drawn to date remains the only amount funded. The forbearance agreement with the holder of the senior secured convertible note expired on June 30, 2026 without extension, and release of the $8,000,000 held under the deposit account control arrangement remains contingent on conversion of the Series A Convertible Preferred Stock in accordance with the note agreement and is not available for general corporate purposes. The $5,000,000 of notes payable that matured on July 1, 2026 were obligations of Lokahi and were derecognized on its deconsolidation.
| 2 |
Results of Operations — Three Months Ended September 30, 2026 Compared to Three Months Ended September 30, 2025
We had no research and development expenses in continuing operations for the three months ended September 30, 2026 or 2025. Research and development expenses of the BioBusiness are included in discontinued operations.
Revenue was $2,898,899 for the three months ended September 30, 2026, compared with nil for the same period in 2025, and consisted of $2,480,000 of software development and deployment services provided by TechyTrade FZ-LLC to two customers under agreements entered into in July 2026. The projects were delivered during the quarter; the related invoices are payable 90 days from the invoice date and the full amount is included in accounts receivable as of September 30, 2026. Revenue also included $418,899 of digital asset yield income from 5.00 bitcoin received under our digital asset yield arrangement, which we present within revenue beginning in the third quarter of 2026 (see Note 2 to the condensed consolidated financial statements). Cost of revenue was $54,300 for the three months ended September 30, 2026 and consisted of the salaries of the TechyTrade FZ-LLC personnel who delivered the projects and a development retainer. General and administrative expenses were $814,477 for the three months ended September 30, 2026. There were no general and administrative expenses in continuing operations for the same period in 2025, when all operating expenses related to the BioBusiness and are presented in discontinued operations. The 2026 amount comprises $746,788 of general and administrative expenses of the Digital Asset segment, principally consultancy, marketing and personnel costs of MindWave, and $67,689 of corporate expenses, including $46,770 of costs that related to the three months ended June 30, 2026 (see Note 11 to the condensed consolidated financial statements).
Total other income, net, was $23,803,716 for the three months ended September 30, 2026, compared with $62,984 for the same period in 2025. The change reflects an unrealized gain on digital assets of $25,264,320, principally from the increase in the quoted price of Bitcoin from $58,415.80 at June 30, 2026 to $83,779.72 at September 30, 2026, and a $340,411 gain from the change in fair value of our derivative liability, partially offset by interest expense of $1,094,953, consisting of accretion of the discounts on our senior secured convertible note, and a $710,705 loss from the change in fair value of our investment in Glucotrack, Inc.
As a result, income from continuing operations was $25,833,838 for the three months ended September 30, 2026, and net income, including income from discontinued operations of $7,812,328, was $33,646,166, or $19.13 per basic share and $7.68 per diluted share, compared with a net loss of $1,781,255, or $1.42 per basic and diluted share, for the same period in 2025.
Results of Operations — Nine Months Ended September 30, 2026 Compared to Nine Months Ended September 30, 2025
We had no research and development expenses in continuing operations for the nine months ended September 30, 2026 or 2025. Research and development expenses of the BioBusiness of $1,860,886 for the nine months ended September 30, 2026 and $1,271,477 for the nine months ended September 30, 2025 are included in discontinued operations.
Revenue was $3,181,630 for the nine months ended September 30, 2026, compared with nil for the same period in 2025, and consisted of $2,480,000 of software development and deployment services, all of which was recognized in the third quarter, and $701,630 of digital asset yield income, including $282,732 received in the second quarter and previously presented within other income (expense). Cost of revenue was $54,300, all of which was incurred in the third quarter. General and administrative expenses were $12,039,229 for the nine months ended September 30, 2026. There were no general and administrative expenses in continuing operations for the same period in 2025. The 2026 amount comprises $8,478,077 of corporate expenses, including the $8,113,318 non-cash charge for advisory shares committed for issuance, and $3,561,152 of general and administrative expenses of the Digital Asset segment.
Total other expense, net, was $11,008,069 for the nine months ended September 30, 2026, compared with other income, net, of $26,666 for the same period in 2025, driven principally by an unrealized loss on digital assets of $9,993,209, interest expense of $2,916,881 and a $710,705 loss from the change in fair value of our investment in Glucotrack, Inc., partially offset by realized and trading gains on digital assets of $2,011,847 and a $604,683 gain from the change in fair value of our derivative liability.
Net loss was $21,586,816, or $12.89 per basic and diluted share, for the nine months ended September 30, 2026, including a loss from discontinued operations of $1,666,848, compared with $4,845,845, or $4.70 per basic and diluted share, for the same period in 2025.
| 3 |
Discontinued Operations. Income from discontinued operations was $7,812,328 for the three months ended September 30, 2026, compared with a loss of $1,844,239 for the same period in 2025, and loss from discontinued operations was $1,666,848 for the nine months ended September 30, 2026, compared with $4,872,511 for the same period in 2025. The 2026 amounts include the $7,803,653 gain on deconsolidation of Lokahi. See Note 3 to the condensed consolidated financial statements.
Segment Results
For the three months ended September 30, 2026, the Digital Asset segment reported income from continuing operations of $27,366,774 and Corporate reported a loss from continuing operations of $1,532,936. For the nine months ended September 30, 2026, the Digital Asset segment reported a loss from continuing operations of $8,419,002 and Corporate reported a loss from continuing operations of $11,500,966. Segment assets as of September 30, 2026 were $145,227,402 for the Digital Asset segment and $8,302,713 for Corporate.
Liquidity and Capital Resources
As of September 30, 2026, we had cash and cash equivalents of $17,912 and restricted cash of $8,000,000, compared with $144,601 and $8,000,000, respectively, as of December 31, 2025, excluding cash of $1,492,054 of Lokahi presented within current assets of discontinued operations. Our restricted cash consists of $8,000,000 held in a deposit account control arrangement for the benefit of the holder of our senior secured convertible note, pending release upon conversion of the Series A Convertible Preferred Stock in accordance with the terms of the note agreement, and is not available for general corporate purposes.
Net cash used in operating activities was $7,953,510 for the nine months ended September 30, 2026, compared with $5,107,575 for the same period in 2025. The 2026 amount reflects our net loss of $21,586,816, adjusted for non-cash items including $9,993,209 of unrealized losses on digital assets, $8,113,318 of advisory shares committed for issuance, $3,805,715 of non-cash accretion of debt discounts, $1,212,398 of accrued but unpaid interest and $218,325 of stock-based compensation, less the $7,803,653 gain on deconsolidation of Lokahi, and for a $2,858,403 increase in accounts payable and accrued expenses, partially offset by a $2,480,000 increase in accounts receivable.
Net cash provided by investing activities was $1,937,420 for the nine months ended September 30, 2026, comprising $2,000,000 of redemptions of short-term investments, partially offset by $53,186 of cash of Lokahi derecognized on its deconsolidation and $9,394 of equipment purchases. Net cash used in investing activities was $35,909 for the same period in 2025.
Net cash provided by financing activities was $4,397,347 for the nine months ended September 30, 2026, comprising $5,970,000 of proceeds from notes payable net of original issue discount, $11,345 of advances from a related party and $1,002 of subscription receivable collected, less $1,000,000 of note repayments and $585,000 of debt issuance costs paid. Net cash provided by financing activities was $12,126,646 for the same period in 2025, principally from our initial public offering and note financings.
Our ability to fund operations depends on our ability to raise additional capital, to monetize our digital-asset holdings, and to repay, extend or restructure our senior secured convertible note. These factors raise substantial doubt about our ability to continue as a going concern.
Critical Accounting Estimates
Our critical accounting estimates include the fair value measurement of our digital assets under ASC 350-60 — in particular the NILA token, which is measured using Level 2 inputs and represented $49,683,723, or 35%, of our digital assets as of September 30, 2026 — the fair value of our investment in Glucotrack, Inc., the fair value of the embedded conversion feature accounted for as a Level 3 derivative liability and measured using a Monte Carlo simulation, and the effective interest rates used to accrete debt discounts. Changes in the assumptions underlying these estimates could have a material effect on our reported results.
| 4 |
Off-Balance-Sheet Arrangements
We do not have any off-balance-sheet arrangements as defined under SEC rules.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
As a smaller reporting company, we are not required to provide the information required by this Item. Notwithstanding the foregoing, our results of operations and financial condition are subject to significant market risk from changes in the fair value of our digital-asset holdings, which are measured at fair value with changes recognized in earnings, and from the equity-price and interest-rate inputs used to value our derivative liability. A hypothetical 10% decline in the fair value of our digital assets as of September 30, 2026 would have reduced our total assets and increased our net loss by $14,242,370.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures. Our management, with the participation of our principal executive officers and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of September 30, 2026. Based on that evaluation, our principal executive officers and principal financial officer concluded that, as of September 30, 2026, our disclosure controls and procedures were not effective, due to material weaknesses in internal control over financial reporting relating to the lack of sufficient qualified accounting personnel, the absence of controls over the review and approval of journal entries, account reconciliations and other fundamental accounting processes, the absence of a formal risk assessment and segregation of duties, and controls over the accounting for complex transactions, including digital assets, convertible instruments and business combinations. These are the same material weaknesses previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025. The evaluation was carried out by Dr. Vin Menon and Sungjoon Chae, our Co-Chief Executive Officers and principal executive officers, together with our principal financial officer.
Changes in Internal Control over Financial Reporting. There were no changes in our internal control over financial reporting during the quarter ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. During the quarter we deconsolidated Lokahi Therapeutics Inc., and our Interim Chief Financial Officer resigned effective September 29, 2026; our Chief Financial Officer was appointed effective October 1, 2026. Management evaluated these changes and concluded that none changed the design or operation of our internal control over financial reporting.
| 5 |
PART II — OTHER INFORMATION
Item 1. Legal Proceedings
From time to time we may be involved in legal proceedings arising in the ordinary course of business. On April 24, 2026 we entered into a Confidential Settlement Agreement and Mutual Release resolving disputes with certain former officers, directors and shareholders, as described in Note 1 and Note 13 to the condensed consolidated financial statements. Other than as described therein, we are not currently a party to any material legal proceedings. In addition, the action captioned Erik Emerson v. Inscobee Inc. and Apimeds, Inc., filed in the United States District Court for the Southern District of New York and disclosed in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, was voluntarily dismissed on May 5, 2026. No amounts were paid by the Company in connection with that dismissal and no liability was recorded.
We are one of approximately 30 defendants, together with the underwriters of certain offerings, in a putative securities class action [caption, court and filing date to be confirmed with counsel]. We have referred the matter to our directors’ and officers’ liability insurance carrier. See Note 13 to the condensed consolidated financial statements.
Item 1A. Risk Factors
There have been no material changes to the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025, other than as follows. Our digital-asset holdings represented 93% of our total assets as of September 30, 2026 and are measured at fair value with changes recognized in earnings; declines in the price of Bitcoin, Tether or the NILA token would have an immediate and material adverse effect on our results of operations and financial condition, and the NILA token trades in markets that are not active, which may limit our ability to monetize that position at its carrying value. Substantial doubt exists about our ability to continue as a going concern. The forbearance arrangement with the holder of our senior secured convertible note expired on June 30, 2026, and the note matures on December 8, 2026; if we are unable to repay, extend or restructure it, the holder may exercise remedies against substantially all of our assets. Although third parties have agreed to make payments to the holder in settlement of its claims, we will not be released from the note unless and until those payments are made in full. Our investment in Glucotrack, Inc. is measured at fair value and is exposed to changes in the market price of Glucotrack common stock. We are not in compliance with Section 1007 of the NYSE American Company Guide and our common stock could be delisted if we do not regain compliance within the cure period. We effected a 1-for-10 reverse stock split on July 24, 2026, which may adversely affect the liquidity and market price of our common stock.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
In connection with the reverse stock split effected July 24, 2026, the Company issued 33,506 shares of common stock as a result of rounding up fractional shares, for no consideration. On September 25, 2026, the Company issued 305,002 shares of common stock to the holder of its senior secured convertible note upon the conversion of $425,000 of principal at a conversion price of $1.3934 per share, pursuant to conversion notices dated September 24, 2026. The shares were issued in reliance on the exemption from registration provided by Section 3(a)(9) of the Securities Act of 1933, as amended, as securities exchanged by the Company with an existing security holder where no commission or other remuneration was paid or given for soliciting the exchange. There were no issuer purchases of equity securities during the three months ended September 30, 2026. As of September 30, 2026, 204,284 shares remained committed but unissued under the advisory agreement described in Note 9 to the condensed consolidated financial statements.
Item 3. Defaults Upon Senior Securities
The holder of the Company’s senior secured convertible note delivered a notice of default under the financing documents and, under a forbearance agreement entered into on April 30, 2026, agreed to forbear from exercising remedies through June 30, 2026. The forbearance period expired on June 30, 2026 and had not been extended as of September 30, 2026. On September 4, 2026, third parties entered into a settlement agreement with the holder; the Company is not a party to that agreement and had not been released by the holder as of September 30, 2026. The notes payable with an aggregate principal amount of $5,000,000 that matured on July 1, 2026 were obligations of Lokahi, were not guaranteed by the Company and were derecognized on the deconsolidation of Lokahi. See Note 8 and Note 3 to the condensed consolidated financial statements.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
During the three months ended September 30, 2026, no director or officer of the Company
| 6 |
Item 6. Exhibits
| 7 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
APIMEDS PHARMACEUTICALS US, INC.
| By: | /s/ Dr. Vin Menon | |
| Dr. Vin Menon, Co-Chief Executive Officer | ||
| (Principal Executive Officer) | ||
| By: | /s/ Sungjoon Chae | |
| Sungjoon Chae, Co-Chief Executive Officer | ||
| (Principal Executive Officer) | ||
| By: | /s/ Eric Sherb | |
| Eric Sherb, Chief Financial Officer | ||
| (Principal Financial Officer and Principal Accounting Officer) | ||
| Date: | November 16, 2026 |
| 8 |